Compare HLSQ & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLSQ | VRAX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.0K | 972.3K |
| IPO Year | 2018 | 2021 |
| Metric | HLSQ | VRAX |
|---|---|---|
| Price | $0.16 | $1.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 292.0K | 152.5K |
| Earning Date | 11-16-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 560.42 | N/A |
| EPS | ★ 3.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.10 |
| 52 Week High | $7.70 | $13.19 |
| Indicator | HLSQ | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 9.04 | 27.04 |
| Support Level | N/A | $0.15 |
| Resistance Level | $2.85 | $2.92 |
| Average True Range (ATR) | 0.32 | 0.14 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 0.63 | 7.46 |
Tessera Defense and Homeland Security Inc develops and acquires technologies that identify, track, and counter physical threats across defense, security, critical infrastructure, and first-response markets - building a portfolio around the growing need for earlier, more accurate threat detection as UAVs and other autonomous systems reshape the operating environment. The Company's portfolio includes Zorronet, an AI-powered autonomous command-and-control platform, and DFSL, a developer of LADAR-based counter-UAS and perimeter security systems.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.